About Veracyte, Inc.
https://www.veracyte.comVeracyte, Inc. operates as a diagnostics company worldwide.
CEO
Marc A. Stapley
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 202
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Guggenheim
Buy
Needham
Buy
UBS
Buy
Stephens & Co.
Overweight
Canaccord Genuity
Hold
Morgan Stanley
Underweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:13.05M
Value:$554.06M
VANGUARD GROUP INC
Shares:8.5M
Value:$361M
BLACKROCK INC.
Shares:7.79M
Value:$330.82M
Summary
Showing Top 3 of 361
About Veracyte, Inc.
https://www.veracyte.comVeracyte, Inc. operates as a diagnostics company worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $131.87M ▲ | $66.24M ▼ | $19.14M ▲ | 14.51% ▲ | $0.24 ▲ | $24.16M ▲ |
| Q2-2025 | $130.16M ▲ | $95.04M ▲ | $-980K ▼ | -0.75% ▼ | $-0.01 ▼ | $6.74M ▲ |
| Q1-2025 | $114.47M ▼ | $76.6M ▲ | $7.05M ▲ | 6.16% ▲ | $0.09 ▲ | $6.53M ▼ |
| Q4-2024 | $118.63M ▲ | $74.58M ▲ | $5.11M ▼ | 4.31% ▼ | $0.07 ▼ | $9.7M ▼ |
| Q3-2024 | $115.86M | $66.99M | $15.15M | 13.08% | $0.2 | $22.73M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $366.43M ▲ | $1.37B ▲ | $110.12M ▼ | $1.26B ▲ |
| Q2-2025 | $320.72M ▲ | $1.34B ▲ | $123.05M ▲ | $1.22B ▲ |
| Q1-2025 | $287.36M ▼ | $1.32B ▲ | $120.47M ▼ | $1.19B ▲ |
| Q4-2024 | $289.44M ▲ | $1.3B ▲ | $124.07M ▲ | $1.18B ▼ |
| Q3-2024 | $274.08M | $1.28B | $98.98M | $1.18B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $19.14M ▲ | $44.76M ▲ | $48.26M ▲ | $2.98M ▲ | $96.07M ▲ | $41.97M ▲ |
| Q2-2025 | $-980K ▼ | $33.6M ▲ | $-224K ▲ | $-566K ▲ | $33.39M ▲ | $32.32M ▲ |
| Q1-2025 | $7.05M ▲ | $5.36M ▼ | $-51.82M ▲ | $-6.48M ▼ | $-52.87M ▼ | $3.54M ▼ |
| Q4-2024 | $5.11M ▼ | $24.52M ▼ | $-54.14M ▼ | $-4.51M ▼ | $-34.53M ▼ | $20.38M ▼ |
| Q3-2024 | $15.15M | $29.96M | $-2.24M | $10.29M | $38.16M | $27.72M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Biopharmaceutical And Other | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Product | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Testing | $220.00M ▲ | $110.00M ▼ | $120.00M ▲ | $130.00M ▲ |
Revenue by Geography
| Region | Q4-2023 | Q4-2024 |
|---|---|---|
 NonUS | $30.00M ▲ | $20.00M ▼ |
 UNITED STATES | $330.00M ▲ | $420.00M ▲ |
CEO
Marc A. Stapley
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 202
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Guggenheim
Buy
Needham
Buy
UBS
Buy
Stephens & Co.
Overweight
Canaccord Genuity
Hold
Morgan Stanley
Underweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:13.05M
Value:$554.06M
VANGUARD GROUP INC
Shares:8.5M
Value:$361M
BLACKROCK INC.
Shares:7.79M
Value:$330.82M
Summary
Showing Top 3 of 361